Cargando…
Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To e...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650793/ https://www.ncbi.nlm.nih.gov/pubmed/33066107 http://dx.doi.org/10.3390/nu12103123 |
_version_ | 1783607555581280256 |
---|---|
author | Amat-Bou, Montse Garcia-Ribera, Sonika Climent, Eric Piquer-Garcia, Irene Corripio, Raquel Sanchez-Infantes, David Villalta, Laia Elias, Maria Jiménez-Chillarón, Josep C. Chenoll, Empar Ramón, Daniel Ibañez, Lourdes Ramon-Krauel, Marta Lerin, Carles |
author_facet | Amat-Bou, Montse Garcia-Ribera, Sonika Climent, Eric Piquer-Garcia, Irene Corripio, Raquel Sanchez-Infantes, David Villalta, Laia Elias, Maria Jiménez-Chillarón, Josep C. Chenoll, Empar Ramón, Daniel Ibañez, Lourdes Ramon-Krauel, Marta Lerin, Carles |
author_sort | Amat-Bou, Montse |
collection | PubMed |
description | Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1′s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo–BPL1 (n = 19) or BPL1–placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480). |
format | Online Article Text |
id | pubmed-7650793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76507932020-11-10 Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial Amat-Bou, Montse Garcia-Ribera, Sonika Climent, Eric Piquer-Garcia, Irene Corripio, Raquel Sanchez-Infantes, David Villalta, Laia Elias, Maria Jiménez-Chillarón, Josep C. Chenoll, Empar Ramón, Daniel Ibañez, Lourdes Ramon-Krauel, Marta Lerin, Carles Nutrients Article Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1′s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo–BPL1 (n = 19) or BPL1–placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480). MDPI 2020-10-13 /pmc/articles/PMC7650793/ /pubmed/33066107 http://dx.doi.org/10.3390/nu12103123 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Amat-Bou, Montse Garcia-Ribera, Sonika Climent, Eric Piquer-Garcia, Irene Corripio, Raquel Sanchez-Infantes, David Villalta, Laia Elias, Maria Jiménez-Chillarón, Josep C. Chenoll, Empar Ramón, Daniel Ibañez, Lourdes Ramon-Krauel, Marta Lerin, Carles Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title | Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title_full | Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title_fullStr | Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title_full_unstemmed | Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title_short | Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial |
title_sort | effects of bifidobacterium animalis subsp. lactis (bpl1) supplementation in children and adolescents with prader–willi syndrome: a randomized crossover trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650793/ https://www.ncbi.nlm.nih.gov/pubmed/33066107 http://dx.doi.org/10.3390/nu12103123 |
work_keys_str_mv | AT amatboumontse effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT garciariberasonika effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT climenteric effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT piquergarciairene effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT corripioraquel effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT sanchezinfantesdavid effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT villaltalaia effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT eliasmaria effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT jimenezchillaronjosepc effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT chenollempar effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT ramondaniel effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT ibanezlourdes effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT ramonkrauelmarta effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial AT lerincarles effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial |